Syncona's Autolus in $250m funding deal with Blackstone Life Sciences

Published date:
November 12 2021

Healthcare investor Syncona on Monday said its portfolio company Autolus Therapeutics had agreed a collaboration and $250m financing deal with Blackstone Life Sciences.

Autolus Therapeutics is a spin out of UCL Business which incorporated Cancer Research UK licensed IP at formation.

The financing agreement includes $100m of immediate equity investment and up to $150 million in product financing.

Blackstone would appoint a member to the Autolus board and receive a capped mid-single digit royalty based on product revenues, Syncona said in a statement.

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of hematological cancers and solid tumors.